期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 103, 期 3, 页码 821-827出版社
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.23848
关键词
recombinant hemagglutinin; influenza; vaccines; potency; Flublok (R); single-radial immunodiffusion assay; mass spectrometry; stability; physicochemical; protein formulation
资金
- Biomedical Advanced Research and Development Authority [HHSO100200900106C]
The recombinant hemagglutinin (rHA)-based influenza vaccine Flublok (R) has recently been approved in the United States as an alternative to the traditional egg-derived flu vaccines. Flublok is a purified vaccine with a hemagglutinin content that is threefold higher than standard inactivated influenza vaccines. When rHA derived from an H3N2 influenza virus was expressed, purified, and stored for 1 month, a rapid loss of in vitro potency (approximate to 50%) was observed as measured by the single radial immunodiffusion (SRID) assay. A comprehensive characterization of the rHA protein antigen was pursued to identify the potential causes and mechanisms of this potency loss. In addition, the biophysical and chemical stability of the rHA in different formulations and storage conditions was evaluated over time. Results demonstrate that the potency loss over time did not correlate with trends in changes to the higher order structure or hydrodynamic size of the rHA. The most likely mechanism for the early loss of potency was disulfide-mediated cross-linking of rHA, as the formation of non-native disulfide-linked multimers over time correlated well with the observed potency loss. Furthermore, a loss of free thiol content, particularly in specific cysteine residues in the antigen's C-terminus, was correlated with potency loss measured by SRID. (c) 2014 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据